{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:14:06Z","timestamp":1779174846726,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med\ufffdInsights\ufffdArthritis\ufffdMusculoskelet Disord"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biologics have revolutionized the treatment of autoimmune rheumatologic diseases, but data on their real-world use and safety in resource-limited settings like Bihar, India, are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the prescription patterns and safety profile of biologic disease-modifying antirheumatic drugs (b-DMARDs) in patients with rheumatoid arthritis (RA) at a tertiary care hospital in Bihar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A prospective, observational cohort study conducted over 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 120 adult patients with RA prescribed b-DMARDs were enrolled. Data on demographic, clinical characteristics, and treatment details were collected. Disease activity (DAS-28-CRP) and functional status (HAQ-DI) were assessed at baseline and 6\u2009months. Adverse events, particularly infections, were recorded and analysed using multivariable logistic regression to identify risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Biologicals were prescribed in 14.93% patients with RA. Adalimumab (49.17%) was the most prescribed b-DMARD, followed by etanercept (28.33%). Methotrexate was the most common concomitant conventional DMARD (85.83%). All b-DMARDs significantly improved DAS-28-CRP and HAQ-DI scores (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.0001), with adalimumab showing the greatest improvement. Infliximab had the highest infection rate (53.33%), whereas etanercept had the lowest (14.70%). Regression analysis identified infliximab use (adjusted odds ratio [aOR]: 3.27), concomitant corticosteroid use (aOR: 2.74), and the presence of comorbidities (aOR: 2.13) as significant independent risk factors for infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Biologic disease-modifying antirheumatic drugs are effective in RA, but infection risks vary. Adalimumab and etanercept demonstrated favourable efficacy and safety profiles, respectively. Treatment decisions should be personalized, considering drug-specific risks, corticosteroid co-therapy, and patient comorbidities, especially in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795441261448563","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:50:36Z","timestamp":1779173436000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar"],"prefix":"10.1177","volume":"19","author":[{"given":"Adil Ali","family":"Shakur","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Indira Gandhi Institute of Medical Sciences, Patna, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raushan Kumar","family":"Ranjan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-2703","authenticated-orcid":false,"given":"Saajid","family":"Hameed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.182"},{"key":"e_1_3_3_3_2","first-page":"77","article-title":"Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy","volume":"66","author":"Yazici Y","year":"2008","unstructured":"Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis. 2008;66:77-85.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070714"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.061002"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.004"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044941"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0073-3"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152811304140915152102"},{"key":"e_1_3_3_15_2","article-title":"The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis","volume":"71","author":"Ruderman EM.","year":"2013","unstructured":"Ruderman EM. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis. Bull Hosp Jt Dis. 2013;71:S29-S32.","journal-title":"Bull Hosp Jt Dis"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01203-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S41645"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17036"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201338"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1515\/hkbrd-2017"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/injr.injr_40_17"},{"key":"e_1_3_3_22_2","unstructured":"Winthrop KL. The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int J Adv Rheumatol. 2010;8:43-52. Accessed April 30 2026. https:\/\/ohsu.elsevierpure.com\/en\/publications\/the-risk-and-prevention-of-tuberculosa-screening-strategies-to-de-2\/"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.4103\/injr.injr_79_18"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70274"}],"container-title":["Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795441261448563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795441261448563","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795441261448563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:50:38Z","timestamp":1779173438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795441261448563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"alternative-id":["10.1177\/11795441261448563"],"URL":"https:\/\/doi.org\/10.1177\/11795441261448563","relation":{},"ISSN":["1179-5441","1179-5441"],"issn-type":[{"value":"1179-5441","type":"print"},{"value":"1179-5441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"11795441261448563"}}